source
- Claris Bio raises $118M Series B and appoints new CEO to advance eye-drug for limbal stem cell deficiencyClaris Bio, a New Jersey biotechnology company, announced a $118 million Series B financing round co-led by Samsara BioCapital and Catalio Capital Management, with participation from Sofinnova Inve…
- Apnimed targets up to $160 million IPO to fund sleep‑apnea drug AD109Apnimed, a sleep‑specialist biotech, announced plans for an initial public offering that could raise up to $160 million in gross proceeds. The company will sell 10 million shares at $14‑$16 each,…